ArticleMolecular therapy. Nucleic acids2019
LncRNA LINC00963 Promotes Tumorigenesis and Radioresistance in Breast Cancer by Sponging miR-324-3p and Inducing ACK1 Expression.
Article in Molecular therapy. Nucleic acids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Non-coding RNAs as modulators of radioresponse in triple-negative breast cancer: a systematic review.Journal of biomedical science · 2024Pooled it
- Effects of noncoding RNAs in radiotherapy response in breast cancer: a systematic review.Cell cycle (Georgetown, Tex.) · 2022Pooled it
- Accurate prediction of candidate lncRNAs associated with DNA damage response based on gene expression patterns from graph neural networks.Bioinformatics advances · 2026Article
- LRRC75A-AS1 facilitates breast cancer cell proliferation and invasion via functioning as a CeRNA to modulate miR489-3p/ARD1.Scientific reports · 2025Article
- Non-coding RNAs modulation in breast cancer radioresponse: mechanisms and therapeutic implications.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Review
- Regulation of Different Types of Cell Death by Noncoding RNAs: Molecular Insights and Therapeutic Implications.ACS pharmacology & translational science · 2025Review
- Article
- ACK1/TNK2 kinase: molecular mechanisms and emerging cancer therapeutics.Trends in pharmacological sciences · 2025Review
- Role of Non-coding RNAs on the Radiotherapy Sensitivity and Resistance in Cancer Cells.Current gene therapy · 2025Review
- Association prediction of lncRNAs and diseases using multiview graph convolution neural network.Frontiers in genetics · 2025Article
- LINC00963 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma by Interacting with miR-10a to Upregulate SKA1 Expression.Applied biochemistry and biotechnology · 2024Article
- Construction of a prognostic risk model for uveal melanoma based on immune-related long noncoding RNA.Medicine · 2024Article
- MicroRNA-mediated epigenetic regulation of HDAC8 and HDAC6: Functional significance in cervical cancer.Non-coding RNA research · 2024Article
- Research progress on factors affecting the sensitivity of breast cancer to radiotherapy: a narrative review.Translational cancer research · 2024Review
- Exploring the enigma: history, present, and future of long non-coding RNAs in cancer.Discover oncology · 2024Review
- Role of ferroptosis and ferroptosis-related long non'coding RNA in breast cancer.Cellular & molecular biology letters · 2024Review
- Elucidating the molecular basis of ATP-induced cell death in breast cancer: Construction of a robust prognostic model.World journal of clinical oncology · 2024Article
- Harnessing the potential of long non-coding RNAs in breast cancer: from etiology to treatment resistance and clinical applications.Frontiers in oncology · 2024Review
- Multiple roles of LncRNA-BMNCR on cell proliferation and apoptosis by targeting miR-145/CBFB axis in BMECs.The veterinary quarterly · 2023Article
- MicroRNA-324-3p inhibits osteosarcoma progression by suppressing PGAM1-mediated aerobic glycolysis.Cancer science · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Retraction · 2025-04-11Concerns/Issues about Image · Concerns/Issues about Referencing/Attributions · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Investigation by Third Party · Manipulation of Images · Plagiarism of Image · · See also: https://pubpeer.com/publications/1DB54946D624578CC3AD79416F3251
- Retracted
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upregulation of long non-coding RNA LINC00963 has been observed in several cancer types. In this study, we analyzed the clinical and biological significance of LINC00963 in breast cancer. The key microRNA (miR) mediating the action of LINC00963 was identified. We show that LINC00963 upregulation is correlated with aggressive parameters of breast cancer. Silencing of LINC00963 suppresses the proliferation and tumorigenesis of breast cancer cells, whereas LINC00963 overexpression exerts an opposite effect. Knockdown of LINC00963 enhances DNA damage and oxidative stress and sensitizes breast cancer cells to radiation. Mechanistically, LINC00963 antagonizes the repressive activity of miR-324-3p on ACK1 expression. Clinically, there is a negative correlation between miR-324-3p and LINC00963 expression in breast cancer tissues. Overexpression of LINC00963 or ACK1 rescues the inhibitory effects of miR-324-3p on breast cancer cell proliferation and radiosensitivity. In addition, knockdown of ACK1 attenuates LINC00963-dependent breast cancer growth and tumorigenesis. Taken together, LINC00963 promotes tumorigenesis and radioresistance in breast cancer through interplay with miR-324-3p and derepression of ACK1. LINC00963 may represent a potential target for the treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.